Opioid marketing under the microscope in day two of Oklahoma trial
A doctor who had been paid speaking and consulting fees by opioid manufacturers testified on Wednesday.
Regulatory
Sooner than you think: Pharma scrambles for drug price ad deadline
The ruling is in. After months of speculation, the Trump administration will require pharma companies to include the list price of a drug in direct-to-consumer TV ads — and sooner than most experts believed.
What’s next for the post-Gottlieb FDA
With the Trump administration putting out fires elsewhere, it could be a long temporary tenure for Dr. Scott Gottlieb’s acting replacement.
Live blog: PBMs face congressional grilling
The latest from the Senate Finance Committee’s grilling of executives from Cigna, CVS Health and CVS Caremark, Humana and OptumRx
MM&M’s annotated guide to the most essential DTC regulations and requirements
MM&M presents its first annotated guide to the most essential DTC regulations and requirements.
Eli Lilly, Johnson & Johnson take initiative, get in front of PhRMA guidelines
Eli Lilly and Johnson & Johnson take the lead on PhRMA’s new guidelines for DTC ads.
Purdue Pharma reaches first opioid-related lawsuit settlement
Purdue is settling a lawsuit brought by Oklahoma for $270 million. It is facing more than 1,600 lawsuits nationwide.
FDA sends warning letter to literal snake oil salesman
NutraPharma claimed its cobra venom products could treat chronic pain for conditions ranging from cancer to addiction.
National Cancer Institute head named acting FDA commissioner
FDA Commissioner Scott Gottlieb said last Tuesday that he’s planning to resign in a few weeks.
What’s next for FDA? Four areas where the agency will have to fill a Gottlieb-sized void
What’s waiting on the desk of the next FDA commissioner.
Want to read more?
Please login or register first to view this content.
